INTRODUCTION
Vaccination is the most efficient way to protect humans against influenza. Several influenza vaccines are currently available, including split subunit vaccines and attenuated viral vaccines (1) . Split vaccines, which are most commonly used, are prepared by culture of the influenza virus in hen eggs or cell cultures, followed by purification and treatment with detergents (2) . In the United States, split vaccines are used without adjuvants, whereas in Europe, some vaccines contain adjuvants such as MF59 or AS03 (3, 4) . Because the composition of influenza vaccines varies annually on the basis of results from global influenza surveillance data, the determination of vaccine effectiveness remains a continuous challenge.
The need for rapid implementation of a vaccination program during the outbreak of the pandemic influenza A(H1N1)pdm09 virus in 2009 led initial studies to focus on immunogenicity rather than overall efficacy of the vaccine. Several influenza vaccines were then marketed, including the trivalent nonadjuvanted seasonal flu vaccine (5) (6) (7) (8) (9) . In contrast, the nonadjuvanted form of MIV-09 displayed lower effectiveness, low seroprotection in healthy children (35%), and suboptimal response in solid organ transplant recipients and children with systemic lupus erythematosus (9) (10) (11) (12) (13) . It is unclear why nonadjuvanted TIV-09 and MIV-09, two vaccines produced by the same manufacturer (Sanofi Pasteur), display such disparate efficacy levels.
Traditionally, vaccine efficacy has been measured by hemagglutinininhibiting antibody response as a correlate of humoral immunity (14) . Some studies suggested that assessment of T cell responses might provide a better correlate of vaccine protection against influenza, especially in the elderly (15) . Other studies suggested that influenza vaccines might differentially activate subpopulations of immune cells (16, 17) . We and others demonstrated that administration of seasonal influenza vaccines to healthy volunteers induces global transcriptional changes in whole blood that can be followed at discrete time points (18) (19) (20) (21) (22) (23) . In particular, a transcriptional signature of interferon (IFN)-inducible genes was observed between 12 and 36 hours after vaccination, followed by a plasmablast signature at day 7 (23) . This early signature may represent an important correlate of vaccine efficacy because type I IFNs enhance antigen crosspresentation to CD8 + T cells, foster T helper 1 differentiation, support B cell differentiation into antibody-producing plasmablasts, and induce dendritic cell (DC) maturation (24) (25) (26) . DCs play an essential role in vaccination by detecting and presenting foreign antigens to adaptive immune cells (27, 28) . We recently showed that different DC subsets, including monocyte-derived DCs (moDCs) and blood conventional DCs (cDCs), respond differently to various bacterial and viral vaccines (29) .
To better understand the biological mechanisms underlying the difference in the effectiveness of nonadjuvanted TIV-09 and MIV-09, we compared their ability to activate human DC subsets. Our results suggest that, in the absence of adjuvant, TIV-09 activates a broader range of DC subsets than MIV-09 in a type I IFN-dependent manner, possibly explaining the increased efficacy of the former vaccine.
RESULTS

TIV-09, but not MIV-09, activates moDCs and induces type I IFN secretion
To assess the effects of TIV-09 and MIV-09 on DC activation, moDCs were obtained by culturing isolated human monocytes in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 6 days and were subsequently exposed to each vaccine for 18 hours. TIV-09 up-regulated the surface expression of hallmark DC maturation markers CD40, CD80, CD83, CD86, human leukocyte antigen (HLA)-DR, programmed death-ligand 1 (PD-L1), PD-L2, and CCR7 (n = 7; Fig. 1A ). Compared to TIV-09, MIV-09 induced significantly (P < 0.01) lower expression of these markers. moDC activation was further assessed by measuring the release of cytokines at different time points after vaccine challenge. IFN-b reached its peak level at 12 hours and decreased to near baseline values after 48 hours, suggesting its consumption. Macrophage inflammatory protein-1b (MIP-1b) reached its peak at 12 hours and slightly decreased thereafter. Other cytokines such as IFN-a, IL-29, IL-6, and IFN-g-inducible protein 10 (IP-10) attained peak levels at 12 to 24 hours and remained stable at 48 hours. Conversely, MIV-09 did not induce cytokine secretion, with the exception of MIP-1b (n = 10; Fig. 1B ). Because TIV (45 mg) contains three times more viral protein than MIV-09 (15 mg), we conducted a dose-dependent analysis. Even at high concentration (greater than fourfold), MIV-09 failed to induce the secretion of IFN-b and IP-10 by moDCs, suggesting that protein concentration cannot explain the observed differences (fig. S1). Staining with PI and annexin V at 4, 8, 12 , and 24 hours also revealed that the lack of cytokines observed with MIV-09 was not due to vaccine-induced cell death (n = 6; Fig. 1C ). We further assessed IP-10 production by moDCs in the presence of other inactivated viral vaccines such as human papillomavirus (Merck), hepatitis A and hepatitis B [GlaxoSmithKline (GSK)], and rabies (Sanofi Pasteur) (table S1). Only TIV-09 induced secretion of IP-10 by moDCs ( fig. S2 ).
Gene expression profiling was performed by microarray on moDCs from six healthy individuals cultured with TIV-09 or MIV-09 for 6 hours. TIV-09 up-regulated all known IFN-a transcripts, IFN-b, IFN-w, and IL-29 (n = 6; Fig. 1D ). Consistent with the protein data, MIV-09 failed to increase the transcription of type I and type III IFN genes. In addition, TIV-09 up-regulated the expression of other proinflammatory and regulatory cytokines, including tumor necrosis factor (TNF), IL-6, IL-1b, and IL-10, which were also slightly up-regulated in response to MIV-09. Together, these results indicate that the seasonal influenza vaccine TIV-09, but not MIV-09, potently activates moDCs, including induction of type I and type III IFNs.
Cell-intrinsic type I IFN production contributes to moDC activation Upon activation, several cell types first transcribe the IFN-b gene, which results in the prompt secretion of IFN-b. IFN-b then binds to the IFN-a receptor (IFNAR), consequently initiating IFN-a production (30, 31) . To determine whether the early secretion of IFN-b by moDCs might contribute to their further activation, we exposed moDCs to TIV-09 in the presence of a blocking anti-IFN-a/bR2 monoclonal antibody. Activation was assayed by measuring the secretion of the IFN-inducible cytokine IP-10. The addition of anti-IFN-a/bR2 antibody abolished IP-10 production and strongly reduced production of IFN-a and IL-29 without affecting that of IFN-b (n = 4; Fig. 2A ). In addition, IFNAR blockade resulted in the up-regulation of IL-1b, TNF, and IL-10, suggesting an autocrine inhibitory loop (32) . The addition of anti-IFN-a/bR2 antibody also partially inhibited the up-regulation of CD80, CD83, CD86, CD70, and CD40 (n = 4; Fig. 2B ), suggesting that moDC maturation is dependent on type I IFN secretion. These data indicate that the early burst of IFN-b production contributes to TIV-09-induced activation of moDCs. To determine whether MIV-09 could inhibit moDC activation, we activated moDCs with TIV-09 or selected Toll-like receptor (TLR) agonists, including LPS (TLR4 ligand), R848 (TLR7/8 ligand), CL097 (TLR7/ 8 ligand), and CD40L, with or without MIV-09. At a concentration of 25 mg/ml, MIV-09 not only completely abrogated the secretion of IP-10 induced by TIV-09 but also the secretion of other IFN-related cytokines, including IFN-b, IL-29, and IL-6 [ Fig. 3 , B (n = 7) and C (n = 3)]. MIV-09 also inhibited the secretion of cytokines by moDCs activated by CD40L and all TLR agonists tested. Because MIV-09 could inhibit the early IFN-b response, we wondered whether the addition of exogenous recombinant IFN-a might reverse the inhibitory effects of MIV-09 on the secretion of other cytokines, which was not the case (n = 7; Fig.  3C ). MIV-09 also prevented the expression of CD80, CD83, CD86, CD70, and CD40 induced by TIV-09 and all DC-activating stimuli tested (n = 4; Fig. 3D ). These results indicate that MIV-09 acts as a potent inhibitor of cytokine secretion and maturation in activated moDCs.
MIV-09 inhibits the IFN response in moDCs
To further understand the molecular alterations induced by both vaccines at the pathway level, we conducted Ingenuity Pathway Analysis (IPA) on the transcriptional fingerprints of vaccine-treated cells (Fig.  3E) . The top pathways associated with TIV-09 exposure included IFN signaling (yellow and blue), protein ubiquitination (blue), IFN regulatory factor (IRF) signaling (yellow), and retinoic acid-mediated signaling (yellow). These pathways were suppressed when moDCs were exposed to MIV-09. On the other hand, MIV-09 enhanced the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway (purple), which can inhibit IFN responses (33) . These results suggest that MIV-09 inhibits IFN signals and moDC maturation by skewing the transcriptional cascade of vaccine-exposed moDC toward ERK-mediated proinflammation.
TIV-09 elicits a type I IFN signature in blood cDCs
Because moDCs and blood cDCs differ phenotypically and functionally, we next assessed the effects of TIV-09 and MIV-09 on sorted ex vivo blood cDCs. As observed in moDCs, the surface expression of CD80, CD83, CD86, and HLA-DR was increased on cDCs exposed to TIV-09 for 18 hours. Exposure to MIV-09 was associated with lower induction of CD80, CD83, and CD86 (n = 4; Fig. 4A ). Although cDCs express significantly lower levels of type I IFNs than pDCs (34), cDCs exposed to TIV-09, but not to MIV-09, displayed up-regulation of both IFNinducible transcripts and IP-10 secretion [ Fig. 4 , B (n = 3) and C (n = 6)]. As observed with moDCs, MIV-09 prevented the TIV-09-dependent secretion of IP-10 by cDCs (n = 6; Fig. 4D ) and down-regulated TIV-09-induced surface expression of CD83, CD86, and HLA-DR (n = 4; Fig. 4E ). These data suggest that MIV-09 also blocks IFN signals in ex vivo cDCs.
Both vaccines elicit a type I IFN signature in blood pDCs
Plasmacytoid dendritic cell (pDCs) promptly secrete large amounts of type I IFNs in response to a number of stimuli including viruses (35) . Therefore, we exposed pDCs to TIV-09 or MIV-09 for 18 hours and assessed the expression of activation markers flow cytometry and IFN transcription by microarray. Both vaccines up-regulated CD80, CD86, and HLA-DR expression, with TIV-09 being consistently more potent than IL1β  TNF  IL6   IFNB1  IL29  IFNA13  IL29  IFNW1  IFNA14  IFNA7  IFNA10  IFNA16  IFNA8  IFNA2  IFNA14  IFNW1  IFNE1  IFNE1  IFNA21  IFNA1  IFNA7   0 1 6 Normalized log ratio 
MIV-09 fails to induce a type I IFN signature in vivo
To better understand the early immune response to influenza vaccination in vivo, we vaccinated healthy individuals with TIV-09, MIV-09, or saline control and assessed the transcriptional profiles of whole blood at 0, 1.5, 3, 6, 9, 12, 15, 24, and 36 hours and 2, 3, and 7 days after vaccination by microarray. Data were analyzed both at the single-transcript level and using a previously described framework of modules of coexpressed transcripts, focusing on three IFN modules (36) . Consistent with previous studies from our group (18) , as well as others (19) (20) (21) (22) (23) , TIV-09 induced a transient type I IFN signature 24 to 48 hours after vaccination. However, this signature was not induced in response to MIV-09 (Fig. 6 ). These results indicate that MIV-09 fails to induce an IFN response in vivo.
DISCUSSION
This study focuses on how nonadjuvanted influenza vaccines that display different effectiveness affect the biological functions of human DC subsets. We first show that the Fluzone vaccines, which do not contain the H1N1 strain A/California/07/2009 X-179A, activate moDCs The graph summarizes data from 10 donors. (B) moDCs were treated with TIV-09 (25 ml/ml) combined with increasing doses of MIV-09 for 8 hours. Supernatants were harvested for enzyme-linked immunosorbent assay (ELISA). The graph summarizes data from seven donors. (C) moDCs were activated with TIV-09 (6 ml/ml), LPS (50 ng/ml), CD40L (1 mg/ml), R848 (3 mg/ml), or CL097 (5 mg/ml) alone or with MIV-09 (10 ml/ml) with or without recombinant IFN-a (2000 U/ml). Supernatant cytokine concentrations were assessed by Luminex. The graph summarizes data from three donors. (D) moDCs were stimulated with TIV-09, LPS, CD40L, R848, or CL097 with or without MIV-09. The surface expression of moDC activation markers was examined by flow cytometry. The figure is representative of experiments in four independent donors. (E) IPA of the transcripts unique to each vaccine and most highly expressed after vaccine exposure. The top three canonical pathways enriched in the transcripts induced by each vaccine are shown (n = 3) (***P < 0.001, Mann-Whitney U test). eIF2, eukaryotic initiation factor 2; mTOR, mechanistic target of rapamycin; PRRs, pattern recognition receptors; JAK1, Janus kinase 1; TYK2, tyrosine kinase 2.
and blood cDCs as revealed by secretion of type I IFNs, IL-6, IL-29, and MIP-1b and increased surface expression of several DC activation markers. Blocking IFN signaling with an anti-IFNAR antibody further revealed the partial dependence of this activation on an early wave of IFN-b production by DCs. TIV-09 also induced pDCs to transcribe and secrete type I IFNs. We then show that the monovalent nonadjuvanted MIV-09, which displayed limited clinical efficacy, (i) did not induce an IFN response and maturation of moDCs and cDCs and (ii) blocked the IFN-mediated activating effects of TIV-09 in vitro and IFN signaling in vivo. These results suggest that, in the absence of adjuvant, certain vaccines, but not others, retain immunogenic properties through IFN-mediated DC activation.
These findings might partly explain why in vivo administration of TIV-09 results in the short-term expression of an IFN signature in circulating blood cells. Type I IFNs play a pivotal role in the induction of adaptive immune responses by promoting the expansion of CD4 + and CD8 + T cells and the maturation of B cells into plasmablasts (24, 26) . High vaccine responses correlate with increased early expression of IFN signaling and antigen processing and presentation (21) . Furthermore, type I IFNs act as powerful adjuvants when administered with influenza vaccine to mice (37) . Thus, one could speculate that the antibody response elicited against TIV-09 might at least, in part, be due to this early IFN response.
On the other hand, MIV-09 was not able to induce moDC and blood cDC activation as measured by secretion of cytokines, including type I IFNA13  IFNA8  IFNA16  IFNB1  IL29  IL6  IFNA10  IFNA14  IFNA7  IFNE1  IFNA2  IFNW1  IFNW1  IFN21 IFNs, and induction of activation markers. Moreover, MIV-09 acted as a powerful inhibitor of the effects of TIV-09 on the production of cytokines, including IFN and induction of activation markers by moDCs and cDCs. Instead, exposure to MIV-09 was associated with a unique transcriptional signature in moDCs that was enriched for ERK/MAPK signaling. Studies with murine macrophages indicate that IFN-b production is inhibited by ERK activation (33), thereby providing a plausible mechanism for the IFN-inhibitory activity of MIV-09 in moDCs and blood cDCs. The inability of MIV-09 to completely shut down the IFN machinery in pDCs may be due to constitutive expression of IRF7 in these cells (38) . Moreover, the combination of MIV-09 with TIV-09 results in production levels of IP-10 that are lower than those induced by TIV-09.
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Normalized log ratio protective antibody responses but differ in the blood transcriptional profiles they elicit (18) . When assessing IP-10 production by moDCs in the presence of other inactivated viral vaccines including human papillomavirus, hepatitis A, hepatitis B, and rabies (table S1), only TIV-09 induced secretion of IP-10 by moDCs ( fig. S2 ). Most seasonal influenza vaccines have been shown to exhibit early IFN signatures (18, (21) (22) (23) , suggesting that type I IFN plays an important role in shaping protective immunity against influenza. Our study shows that, unlike seasonal influenza vaccines, MIV-09 fails to exhibit the classic type I IFN signature in vitro and in vivo.
Higher effectiveness has been observed in MIV-09 supplemented with squalene-based adjuvants MF59 and AS03, as compared with its nonadjuvanted form (3, 4) . Several observations support a direct effect of MF59 on DCs. MF59 rapidly localizes to intracellular DEC-205 + DC compartments after injection in mice (39) , promotes recruitment of human myeloid cells to the injection site, enhances DC maturation and antigen uptake, and facilitates DC migration to draining lymph nodes (40) . A recent study in mice also demonstrated that MF59 promotes the retention of unprocessed antigen within the lymph nodes, thereby facilitating antigen encounters with follicular DCs (41) . Whether these two adjuvants can induce the IFN response in DCs is still unknown.
Because of the presence of broadly cross-reactive antibody responses as a result of prior vaccination or infection (42, 43) , it will be challenging to determine whether the lack of in vitro and in vivo activation of type I IFN signature reflects the reduced immunogenicity of MIV-09 as compared to TIV-09. Vaccines against pneumococcus or rabies are fully immunogenic in vivo despite lacking interferogenic properties in DC in vitro (29) . These observations suggest the existence of IFN-dependent and IFN-independent mechanisms for mounting immune responses against specific pathogens.
Our study is limited by its in vitro nature. Our model of vaccineexposed moDC and sorted blood DC does not fully represent molecular and cellular events occurring in situ after vaccination. In particular, it does not account for DC activation mechanisms that can be triggered indirectly through the recruitment of other inflammatory cell populations. The phenotype of the DC populations studied may also not accurately reflect the phenotype of DCs found in skin and muscle, especially that of Langerhans cells.
Together, this study sheds light on the mechanisms of DC activation by influenza vaccines. Furthermore, it highlights the differences between nonadjuvanted influenza vaccines in inducing IFN and proinflammatory responses in vitro and in vivo, further unraveling the Normalized log ratio mechanisms of action of vaccines at the systemic level and the role of early inflammatory responses in the process of vaccination. In vitro DC culture and stimulation moDCs were generated from monocytes isolated from healthy donor apheresis fractionated by elutriation. Monocytes were enriched by negative selection using EasySep Human Monocyte Enrichment Kit without CD16 depletion (STEMCELL Technologies) and cultured in CellGro DC medium (CellGenix) with 1% penicillin/streptomycin. Cells were cultured in sterile 50-ml tissue culture bags (American Fluoroseal Corporation) at an initial density of 1 × 10 6 cells/ml along with GM-CSF at 10 ng/ml and IL-4 (R&D Systems) at 50 ng/ml for 6 days. Cells were supplemented with additional cytokine doses at days 2 and 4. At day 6, DCs were harvested and further cultured in 200 ml of RPMI 1640 supplemented with 1% glutamine, 1% penicillin/streptomycin, 1% Hepes, 1% non-amino acids, 1% sodium pyruvate, 0.1% b-mercaptoethanol (Invitrogen), and 10% fetal bovine serum at a density of 1 × 10 5 cells/ml in 96-well plates. TIV-09 (45 mg of viral protein; 6 ml/ml) and/or MIV-09 (15 mg of viral protein; 6 ml/ml) (Sanofi Pasteur) was added, and cells were incubated at 37°C for 0, 6, 12, 24, and 48 hours. Supernatants were collected and stored at −80°C.
METHODS
Another set of experiments was performed with Fluzone from different vaccination seasons. moDCs were exposed for 8 A separate experiment was performed to assess IP-10 production by moDCs in the presence of other inactivated viral vaccines such as human papillomavirus (Merck), hepatitis A, hepatitis B (GSK), and rabies (Sanofi Pasteur). moDCs were treated with vaccines for 18 hours. Supernatants were stored at −80°C.
DC phenotype and cytokine assay DCs (1 × 10 5 ) were stimulated with selected vaccines for 18 hours and labeled with fluorochrome-conjugated anti-CD83, anti-CD80, anti-CD86, anti-HLA-DR, anti-PD-L1, anti-PD-L2, anti-CCR7, and anti-CD40 antibodies (BD Biosciences). Cell death was assessed by annexin V and PI staining (BD Biosciences). Labeled cells were analyzed using a FACSCanto (BD Biosciences). IP-10 (BD Biosciences) and IFN-b (R&D Systems) levels were measured by ELISA, and other cytokines were assessed using bead-based cytokine multiplex analysis (Luminex, Bio-Rad). ) were cultured with vaccine (6 ml/ml) in a 0.5-ml complete medium for 6 hours and processed for RNA analysis.
Purification and activation of pDCs and cDCs
RNA processing and transcriptional analysis
After vaccine stimulation, cells were lysed in an RLT buffer (RNeasy Plus Mini Kit, Qiagen) supplemented with 1% b-mercaptoethanol and stored at −80°C. Total RNA was isolated from cell lysates according to the manufacturer's instructions. RNA from samples passing quality control was amplified and labeled with Illumina TotalPrep RNA Amplification Kit (Illumina). RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). Biotinylated complementary RNA was hybridized to Illumina Human-6 BeadChip Array version 2 and scanned in Illumina BeadStation 500. Fluorescent hybridization signals were assessed with BeadStudio software (Illumina). Statistical analysis and hierarchical clustering were performed with GeneSpring 7.3.1 software (Agilent Technologies). For the vaccinated healthy cohort, data were normalized to the median of the t = 0 hour samples across donors.
Statistical analysis
Data from cell culture experiments were expressed as mean of replicate experiments. Statistical significance was determined by nonparametric test such as Mann-Whitney U test. P < 0.05 was considered statistically significant. For microarray analysis, unless otherwise specified, we conducted Welch's unequal variances t test (P < 0.01), adjusting the false discovery rate with the Benjamini-Hochberg procedure. For all figures, horizontal lines or bars represent the mean, and whiskers represent the SD.
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